Find research datasets worth reusing

opencc-by-4.0Nov 2020View details →

Data supplement for "Efficient calculation of phase coexistence and phase diagrams: application to a binary phase-field crystal model"

This dataset contains the data and source files for the diagrams of the following publication: Holl, M. P., Archer, A.J., & Thiele, U. Efficient calculation of phase coexistence and phase diagrams: application to a binary phase-field crystal model arXiv preprint <a href="https://arxiv.org/abs/2009.02946">arXiv:2009.02946</a>, 2020 We provide the data and sources necessary to generate figures 10-14 of the manuscript. Additionally we provide the MATLAB codes to run all the continuations for the results in sections 4.2 and 5.  For more information, please see the included README.md

opencc-zeroJan 2021View details →

Supplemental material for: PROMISE-2: Efficacy and safety of eptinezumab in patients with chronic migraine

Objective: To evaluate the efficacy and safety of eptinezumab, a humanized anti–calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM). Methods: The PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy–2 (PROMISE-2) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with CM were randomly assigned to receive intravenous (IV) eptinezumab 100 mg, eptinezumab 300 mg, or placebo, administered on day 0 and week 12. The primary endpoint was change from baseline in mean monthly migraine days (MMDs) over weeks 1–12. Results: Among treated participants (n = 1072), baseline mean MMDs was ~16.1 across groups. Treatment with eptinezumab 100 mg and 300 mg was associated with significant reductions in MMDs across weeks 1–12 compared with placebo (placebo, −5.6, 100 mg, −7.7, p < 0.0001 vs placebo; 300 mg, −8.2, p < 0.0001 vs placebo). Treatment-emergent adverse events (TEAEs) were reported by 43.5% (100 mg), 52.0% (300 mg), and 46.7% (placebo) of patients. Nasopharyngitis was the only TEAE reported for >2% of eptinezumab treated patients at an incidence of greater than 2% over placebo; it occurred in the 300 mg eptinezumab arm (eptinezumab 9.4%, placebo 6.0%). Conclusion: In patients with CM, eptinezumab 100 mg and 300 mg was associated with a significant reduction in MMDs from the day following IV administration through week 12, was well tolerated, and demonstrated an acceptable safety profile.

opencc-zeroJun 2021View details →

Midlife Plasma AB and Latelife Risk of MCI/Dementia Supplemental Material

Objective. To evaluate the association between midlife plasma amyloid-beta (Aβ1-42, Aβ1-40, Aβ42:Aβ40) and risk of MCI and dementia. Plasma Aβ42 and Aβ40 were retrospectively measured using a fluorimetric bead-based immunoassay in a subsample of the Atherosclerosis Risk in Communities study (n=2284) at the third (1993-95, mean age=59.2±5.2, 57% female, 22% Black) and fifth in-person visits (2011-13, mean age=77.0±5.3). We investigated the relationship of plasma Aβ42, Aβ40, and Aβ42:Aβ40 ratio measured in midlife, late-life, and the change from midlife to late-life, to risk of MCI, dementia, and combined MCI/dementia outcomes in late-life (from 2011-19). We used multinomial logistic regressions estimating relative risk ratios (RRR) of these cognitive outcomes vs cognitively normal adjusted for age, sex, education, site-race, APOE, hypertension, diabetes, and body mass index. Each doubling of midlife Aβ42:Aβ40 was associated with 37% lower risk of MCI/dementia (RRR=0.63, 95% CI: 0.46, 0.87), but only up to approximately the median (spline model threshold 0.20). Every standard deviation increase in plasma Aβ42 (10 pg/mL) was associated with 13% lower risk of MCI/dementia (RRR=0.87, 95% CI: 0.77, 0.98), whereas every standard deviation increase in plasma Aβ40 (67 pg/mL) was associated with 15% higher risk of MCI/dementia (RRR=1.15, 95% CI: 1.01, 1.29). Associations were comparable, but slightly weaker statistically, when repeating models using late-life plasma Aβ predictors. Aβ42 and Aβ40 increased from midlife to late-life, but changes were not associated with cognitive outcomes. Midlife measurement of plasma Aβ may have utility as a blood-based biomarker indicative of risk for future cognitive impairment.

opencc-by-4.0Apr 2016View details →

Berends_vandeWal_2016_GMD_supplement

Data files required to run the Matlab scripts provided as a supplement to the paper by Berends and van de Wal in GMD, 2016.

opencc-by-4.0Apr 2023View details →

Self Supervised Cloud Classification Data Supplement

Supplementary data for: "Self Supervised Cloud Classification" Geiss et al. 2023. Includes trained neural networks and a copy of the image chips extracted from the "SGFF" dataset that were used for evaluating the trained networks. Update 9-16-2025: Uploaded the correct 'modis_encoder' file. Previously the 'modis_projector' file was mistakenly uploaded as both the encoder and projector.

opencc-by-4.0Jan 2024View details →

Pareto Curves for Compositionally Model Checking String Diagrams of MDPs: Supplemental Material

Supplemental material for the paper: Pareto Curves for Compositionally Model Checking String Diagrams of MDPs Submitted to TACAS 2024

opencc-by-4.0Feb 2024View details →

Figure 1 from: Abu-Zaid A, Abu-Zaid S, Barakat M, Al-Huniti R, Khair H (2024) Effectiveness of combination therapy of magnesium, vitamin B2 and Co-enzyme 10 supplementation on vestibular migraine: a retrospective cohort study. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e112909

Figure 1 Decrease in vestibular migraine symptom duration following supplementation (n = 57).

opencc-by-4.0Feb 2024View details →

Figure 3 from: Abu-Zaid A, Abu-Zaid S, Barakat M, Al-Huniti R, Khair H (2024) Effectiveness of combination therapy of magnesium, vitamin B2 and Co-enzyme 10 supplementation on vestibular migraine: a retrospective cohort study. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e112909

Figure 3 Decrease in frequency of vestibular migraines following supplementation (n = 57).

opencc-by-4.0Feb 2024View details →

Figure 2 from: Abu-Zaid A, Abu-Zaid S, Barakat M, Al-Huniti R, Khair H (2024) Effectiveness of combination therapy of magnesium, vitamin B2 and Co-enzyme 10 supplementation on vestibular migraine: a retrospective cohort study. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e112909

Figure 2 Decrease in severity of vestibular migraine following supplementation (n = 57).

opencc-by-4.0Jul 2024View details →

Supplements for "The Proteomic Code: Novel Amino Acid Residue Pairing Models "Encode" Protein Folding and Protein-Protein Interactions"

Supplements for "The Proteomic Code: Novel Amino Acid Residue Pairing Models “Encode” Protein Folding and Protein-Protein Interactions" This supplement includes the following files: <ul> <li>Main_v02.R --- Script in R language to process protein structures and produce the datasets.</li> <li>datasets_v02.zip --- final filtered version of datasets produced in R language (by "Main_v02.R").   </li> <li>Dataset key v02.txt --- key and descriptions to column names in ("datasets.zip").    </li> </ul> The article featuring these datasets is submitted to: Journal:  Computers in Biology and Medicine  (Reference: CBM_110033) Title: "The Proteomic Code: Novel Amino Acid Residue Pairing Models "Encode" Protein Folding and Protein-Protein Interactions" Authors: Hameduh, Tareq; Miller, Andrew D. ; Heger, Zbynek; Haddad, Yazan

opencc-by-4.0Oct 2021View details →

Figure 2 from: Koleva P, Tsanova-Savova S, Paneva S, Velikov S, Savova Z (2021) Polyphenols content of selected medical plants and food supplements present at Bulgarian market. Pharmacia 68(4): 819-826. https://doi.org/10.3897/pharmacia.68.e71460

Figure 2 Chromatogram of Sambucus nigra fruit at 275 nm (a) and at 355 nm (b).

opencc-by-4.0Oct 2021View details →

Figure 3 from: Koleva P, Tsanova-Savova S, Paneva S, Velikov S, Savova Z (2021) Polyphenols content of selected medical plants and food supplements present at Bulgarian market. Pharmacia 68(4): 819-826. https://doi.org/10.3897/pharmacia.68.e71460

Figure 3 Chromatogram of Sambucus nigra food supplement at 275 nm (a) and at 355 nm (b).

opencc-by-4.0Jan 2022View details →

Hölzchen et al. (2022) Supplement B. Supplementary data

This dataset contains Supplement B (supplementary data) for Hölzchen et al. (2022) "Estimating crossing success of human agents across sea straits out of Africa in the Late Pleistocene".

Figure 3 from: Tzankova D, Mateeva A, Mitkov J, Peikova L, Georgieva M (2022) Development and validation of RP-HPLC method for analytical characterization of the anabolic steroid Methenolone acetate in food supplements. Pharmacia 69(1): 151-155. https://doi.org/10.3897/pharmacia.69.e78176

Figure 3 Chromatogram of Methenolone standard solution.

Figure 2 from: Tzankova D, Mateeva A, Mitkov J, Peikova L, Georgieva M (2022) Development and validation of RP-HPLC method for analytical characterization of the anabolic steroid Methenolone acetate in food supplements. Pharmacia 69(1): 151-155. https://doi.org/10.3897/pharmacia.69.e78176

Figure 2 Linearity of the developed RP-HPLC method.

Figure 5 from: Tzankova D, Mateeva A, Mitkov J, Peikova L, Georgieva M (2022) Development and validation of RP-HPLC method for analytical characterization of the anabolic steroid Methenolone acetate in food supplements. Pharmacia 69(1): 151-155. https://doi.org/10.3897/pharmacia.69.e78176

Figure 5 Chromatogram of test solution.

Figure 4 from: Tzankova D, Mateeva A, Mitkov J, Peikova L, Georgieva M (2022) Development and validation of RP-HPLC method for analytical characterization of the anabolic steroid Methenolone acetate in food supplements. Pharmacia 69(1): 151-155. https://doi.org/10.3897/pharmacia.69.e78176

Figure 4 Chromatogram of Methenolone acetate standard solution.

Figure 1 from: Tzankova D, Mateeva A, Mitkov J, Peikova L, Georgieva M (2022) Development and validation of RP-HPLC method for analytical characterization of the anabolic steroid Methenolone acetate in food supplements. Pharmacia 69(1): 151-155. https://doi.org/10.3897/pharmacia.69.e78176

Figure 1 Structure of Methenolone.

opencc-zeroMar 2022View details →

Supplemental Table: Video breakdown of 1,895 NeuroByte user satisfaction survey responses

Objective To determine whether NeuroBytes is a helpful e-Learning tool in neurology through usage, viewer type, estimated time and cost of development, and post-course survey responses. Background A sustainable continuing professional development (CPD) system is vital in neurology due to the field's expanding therapeutic options and vulnerable patient populations. In an effort to offer concise, evidence based updates to a wide range of neurology professionals, the AAN launched NeuroBytes in 2018. NeuroBytes are brief (<5 min) videos that provide high-yield updates to AAN members. Methods NeuroBytes was beta tested from August–December 2018 and launched for pilot circulation from January–April 2019. Usage was assessed by quantifying course enrollment and completion rates; feasibility by cost and time required to design and release a module; appeal by user satisfaction; and impact by self-reported change in practice. Results A total of 5,130 NeuroBytes enrollments (1,026±551/month) occurred from January 11–May 28, 2019 with a median of 588 enrollments per module (interquartile range, 194-922) and 37% course completion. The majority of viewers were neurologists (54%), neurologists in training (26%), and students (8%). NeuroBytes took 59 hours to develop at an estimated $77.94/hour. Of the 1,895 users who completed the survey, 82% were "extremely" or "very likely" to recommend NeuroBytes to a colleague and 60% agreed that the depth of educational content was "just right." Conclusions NeuroBytes is a user-friendly, easily accessible CPD product that delivers concise updates to a broad range of neurology practitioners and trainees. Future efforts will explore models where NeuroBytes combines with other CPD programs to impact quality of training and clinical practice.